Progenics pylarify injections and supporting materials for the louisville VAMC.
Ended Awarded Last action
- Contract number
- 36C24925F0031
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 9
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $218,523
Award facts
- Contract value 8% obligated
-
- $1,283,095.60 Current, with exercised options
- $2,862,138.80 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$16,044 | |
| Funding Only Action | $234,567 | |
| Original award | $0 |
About this award
This delivery order, awarded October 1, 2024, to Progenics Pharmaceuticals Inc. (operating as a division of Lantheus Medical Imaging, Inc.) represents a $2.86M ceiling value contract for the supply of PYLARIFY injections and supporting materials to the Louisville Veterans Affairs Medical Center. The award constitutes a modification that increases the quantity of a prior delivery order by 65 percent. Issued by Veterans Integrated Service Network 9 (a component of the Department of Veterans Affairs), this firm fixed-price contract is not designated as a set-aside and will be performed at the contractor's manufacturing and distribution facility in North Billerica, Massachusetts, with an ultimate completion date of September 30, 2029. PYLARIFY (piflufolastat F-18) is a radioactive diagnostic imaging agent used in positron emission tomography scans for the detection and localization of prostate cancer, providing critical diagnostic capabilities for veterans receiving care through the VA healthcare system.
This delivery order operates under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), a General Services Administration master contract vehicle, and reflects the established federal contracting relationship between Progenics Pharmaceuticals and the VA. Progenics maintains multiple blanket purchase agreements and indefinite delivery vehicles across the VA's 23 Veterans Integrated Service Networks, with individual master contracts valued up to $9.07 million and completion dates extending through 2030. The contractor has received over 150 federal contract awards from the Department of Veterans Affairs, Defense Health Agency, and National Institutes of Health for radiopharmaceutical procurement, establishing the company as a primary supplier of specialized nuclear medicine products supporting oncology imaging programs across federal healthcare providers.
Quick answers
Who was awarded contract 36C24925F0031?
36C24925F0031 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 9 (Veterans Health Administration) on October 1, 2024.
How much is contract 36C24925F0031 worth?
The government has obligated $218,523 on 36C24925F0031. Its current value, with exercised options, is $1,283,096. Its potential value, with all options, is $2,862,139.
Is contract 36C24925F0031 an order under another contract?
Yes. 36C24925F0031 is a delivery order under 36F79719D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24925F0031 competed?
The extent of competition for 36C24925F0031 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award